The final validation of Rev1ΔfbaΔtal in the natural host, in terms of residual virulence, protection, and reproductive safety, will help to verify this Rev1-derived candidate as a new improved vaccine against brucellosis with a lower abortifacient potential, which may facilitate the successful pursuing of mass vaccination campaigns in endemic areas. The gene discussed is REV1; the disease is brucellosis.